Zevra Therapeutics (ZVRA) Current Assets (2014 - 2026)

Zevra Therapeutics has reported Current Assets for 13 years, with the latest figure at $230.0 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 181.92% year-over-year to $230.0 million; the trailing twelve-month figure through Mar 2026 stood at $230.0 million (up 181.92% YoY), and the FY2025 full-year result was $223.0 million, up 159.23% from the prior year.
• Current Assets for Q1 2026 stood at $230.0 million, up from $223.0 million in the prior quarter.
• The five-year high for Current Assets was $230.0 million in Q1 2026, with the low at -$426000.0 in Q1 2022.
• Historically, Current Assets has averaged $118.0 million across 5 years, with a median of $90.1 million in 2022.
• Annual changes were most pronounced in 2022 — Current Assets sank 100.49% — and 2023, when it soared 24578.87%.
• Zevra Therapeutics' Current Assets stood at $92.8 million in 2022, then slipped by 6.35% to $86.9 million in 2023, then declined by 1.05% to $86.0 million in 2024, then jumped by 159.23% to $223.0 million in 2025, then climbed by 3.12% to $230.0 million in 2026.
• The last three Current Assets figures came in at $230.0 million (Q1 2026), $223.0 million (Q4 2025), and $225.1 million (Q3 2025), per Business Quant data.